Industries > Pharma > Biological Drug API Manufacturing Services World Industry and Market Predictions 2016-2026
Back to Pharma Reports

Biological Drug API Manufacturing Services World Industry and Market Predictions 2016-2026

Mammalian Cell Culture, Microbial Fermentation, Human Growth Hormones, Insulin, Interferons, Monoclonal Antibodies, Vaccine

PUBLISHED: 15 August 2016
PAGES: 238
PRODUCT CODE: PHA0137
SUBMARKET: Contract Services

Clear
WOOCS 2.2.1
DOWNLOAD FREE SAMPLE
SKU: PHA0137 Categories: ,

Biological Drug API Manufacturing Services World Industry and Market Predictions 2016-2026: Mammalian Cell Culture, Microbial Fermentation, Human Growth Hormones, Insulin, Interferons, Monoclonal Antibodies, Vaccine reviews the contract active pharmaceutical ingredient (API) manufacturing market for biologics. This study gives quantitative and qualitative analysis for that overall world market, as well as for countries and other submarkets, including the mammalian cell culture and microbial fermentation segments. This report assesses leading applications and significant developments within each, as well as drivers and restraints for them. Future trends that will affect the biotech API manufacturing services market are also examined. In addition, this study profiles leading contract manufacturing organisations (CMOs) in the outsourcing market and assesses their outlooks. Visiongain provides forecasts revenues for the period 2015 to 2026 for the biotech API manufacturing services market, as well as for therapeutic applications.

How this 238 page report delivers:

• Provides qualitative and quantitative analysis of the leading submarkets the period 2015-2026. Visiongain forecasts revenues and their growth for these submarkets:
– Mammalian cell culture
– Microbial fermentation
– Other expression platforms

• Provides qualitative and quantitative analysis of the leading contract API biological drug applications for the period 2015-2026. Visiongain forecasts contract API drug revenues to 2026 for these individual segments:
– Monoclonal antibody (mAb) therapies
– Vaccines
– Insulin therapies
– Interferon therapies
– Growth hormones

• Find forecasts of the leading therapeutic and national markets from 2015 to 2026:
– The EU, including the five leading markets (UK, Germany, France, Italy and Spain).
– The US
– Japan
– Switzerland
– Emerging markets such as the BRIC (Brazil, Russia, India, and China) countries, South Korea and Singapore.

• Profiles leading global and national companies that offer biotech API manufacturing services to the pharmaceutical industry. For each company, current services offered, recent developments and outlooks are discussed. Leading CMOs profiled in this chapter are:
– Boehringer Ingelheim BioXcellence
– Celltrion
– DSM Biologics
– Lonza
– Samsung BioLogics
– Cytovance Biologics
– Fujifilm Diosynth Biotechnologies
– Operations of leading biopharma companies, such as AbbVie, GSK and Novartis.

• Discover the regulatory outlook for biotech API manufacturing in leading regional and national markets in 2016, as well as predicted developments for the period to 2026.
• Read expert opinions from other authorities on the biotech API manufacturing industry.
• Identify important drug development and technology trends that will affect CMOs, their clients and other market participants from 2016. The report also contains SWOT and STEP analysis of the industry and market.
• Find profiles for leading CMOs offering biological drug API manufacturing services to pharmaceutical companies.

Biological Drug API Manufacturing Services World Industry and Market Predictions 2016-2026

How This Report Delivers: Chapter Summary
This updated study provides an overview of the subject along with qualitative and quantitative analyses of the biotech API manufacturing services market. This report contains expert opinions from industry participants. In more detail, the chapters of this report contain the following information:

Chapter 1 forms a report overview.

Chapter 2 defines the biotech API manufacturing services market and provides an introduction to that industry.

Chapter 3 quantitatively assesses the world market for biotech API manufacturing services revenues. The chapter provides an estimate for the size of the market in 2015 and forecasts revenues for the period 2015-2026. Visiongain discusses the main drivers and restraints on the market for a 10-year forecast period.

Chapter 4 provides qualitative and quantitative analysis of the leading submarkets the period 2015-2026. Visiongain forecasts revenues and their growth for these submarkets:
• Mammalian cell culture
• Microbial fermentation
• Other expression platforms.

For the leading submarkets, we analyse commercial drivers and restraints, as well as forecasting revenues to 2026.

Chapter 5 provides qualitative and quantitative analysis of the leading contract API biological drug applications for the period 2015-2026. Visiongain forecasts contract API drug revenues to 2026 for these individual segments:
• Monoclonal antibody (mAb) therapies
• Vaccines
• Insulin therapies
• Interferon therapies
• Growth hormones.

Chapter 6 forecasts the leading national submarkets for biotech API manufacturing services, for the period 2015-2026. That section also provides quantitative analysis. The chapter offers a regional breakdown of the market by market share, and also discusses developments and future expectations for each main national submarket. National submarkets forecasted in this chapter are these:
• The EU, including the five leading markets (UK, Germany, France, Italy and Spain).
• The US
• Japan
• Switzerland
• Emerging markets such as the BRIC (Brazil, Russia, India, and China) countries, South Korea and Singapore.

Chapter 7 profiles leading global and national companies that offer biotech API manufacturing services to the pharmaceutical industry. For each company, current services offered, recent developments and outlooks are discussed. Leading CMOs profiled in this chapter are:
• Boehringer Ingelheim BioXcellence
• Celltrion
• DSM Biologics
• Lonza
• Samsung BioLogics
• Cytovance Biologics
• Fujifilm Diosynth Biotechnologies
• Operations of leading biopharma companies, such as AbbVie, GSK and Novartis.

Chapter 8 provides qualitative analysis of the biotech API manufacturing services market from 2015. That chapter identifies main strengths and weaknesses of the market, as well as opportunities and threats facing CMOs to 2026. Social, technological, economic and political (STEP) factors affecting market growth are also discussed. Industry trends and regulatory developments affecting the market are discussed.

Chapter 9 provides transcripts of interviews conducted by Visiongain with other authorities. For this report, Visiongain interviewed the following authorities on the CMO industry:
• Steve Bagshaw, CEO, Fujifilm Diosynth Biotechnologies, UK.
• Jon S. Gingrich, Manager of Business Development, Avid Bioservices Inc., US.

Chapter 10 summarises the report, highlighting conclusions from Visiongain’s research and analysis.

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6

Download sample pages

Complete the form below to download your free sample pages for Biological Drug API Manufacturing Services World Industry and Market Predictions 2016-2026


Download sample pages

Complete the form below to download your free sample pages for Biological Drug API Manufacturing Services World Industry and Market Predictions 2016-2026


Connect with us

Visiongain Pharma

Visiongain Pharma

Visiongain Pharma

Latest Pharma news

Visiongain Publishes Dermatological Drugs Market Report 2021-2031

The global market for dermatological drugs is ascending and has made significant gains in skin treatments. The players in the dermatological drugs market are striving to tap the opportunities that this market offers.

18 January 2021

READ

Visiongain Publishes Biological API Manufacturing Services Market Report 2021-2031

Demand in the early years of the forecast period will come from multinational biotech looking to sign deals with Indian companies and take advantage of the cheaper costs of production for the emerging market.

08 January 2021

READ

Visiongain Publishes Anaesthesia & Respiratory Devices Market Report 2020-2030

The growth can be attributed to the rising prevalence of respiratory diseases, growing awareness for respiratory diseases, and innovations in respiratory and anesthesia devices. However, unfavourable reimbursement policies and lack of patient adherence in respiratory diseases are some of the factors restraining the growth of the anesthesia and respiratory devices market.

07 January 2021

READ

Visiongain Publishes Inactivated Vaccines Market Report 2020-2030

Factors such as rise in the prevalence of the infectious and bacterial diseases and active participation of government in vaccine development are driving the growth of this market. While high cost of vaccine development is the key factor emerging as a growth barrier over years in this market.

07 January 2021

READ

Categories

Category